Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma

RATIONALE: Glioblastoma multiforme (GBM) is a primary brain tumor with poor prognosis. The U.S. food and drug administration approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this treatment is frequent and fails to enhance the overall survival of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshkon, Ahmad, Tabouret, Emeline, Traboulsi, Wael, Bachelier, Richard, Simoncini, Stéphanie, Roffino, Sandrine, Jiguet-Jiglaire, Carine, Badran, Bassam, Guillet, Benjamin, Foucault-Bertaud, Alexandrine, Leroyer, Aurelie S., Dignat-George, Françoise, Chinot, Olivier, Fayyad-Kazan, Hussein, Bardin, Nathalie, Blot-Chabaud, Marcel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590138/
https://www.ncbi.nlm.nih.gov/pubmed/36274147
http://dx.doi.org/10.1186/s40478-022-01451-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590138/
https://www.ncbi.nlm.nih.gov/pubmed/36274147
http://dx.doi.org/10.1186/s40478-022-01451-3

Ejemplares similares